Fig. 2
From: Delivery of engineered extracellular vesicles with miR-29b editing system for muscle atrophy therapy
EVs-Cas9-miR-29b inhibits the expression of miR-29b by gene editing. a qRT-PCR analysis of the expression of miR-29b in C2C12 myotubes after treatment with EVs-Cas9-29b at different doses (n = 6 per group). b qRT-PCR analysis of the expression of miR-29a and miR-29c in C2C12 myotubes after treatment with EVs-Cas9-29b at a dose of 1 × 1010 particles/mL (n = 6 per group). c Diagram of miR-29b pre-miRNA hairpin structure and the protospacer adjacent motif (PAM) for the gRNA. And T7EI assays for the mutation at the miR-29b-1 and miR-29b-2 in C2C12 myotubes treated with EVs-Cas9-29b. d Western blot analysis for the Cas9 protein in C2C12 myotubes after treatment with EVs-Cas9-29b, AAV8-SaCRISPR-miR-29b and Lenti-CRISPR-miR-29b. e qRT-qPCR analysis of the expression of miR-29b in C2C12 myotubes after treatment with EVs-Cas9-29b, AAV8-SaCRISPR-miR-29b and Lenti-CRISPR-miR-29b for 24 h (n = 6 per group). Data were presented as mean ± SD. Statistical significance was determined using Student t test (a,b,e). *P < 0.05; **P < 0.01; ns, no significance